abstract |
A composition for use in the treatment of cancer comprising a physiologically acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for a variant histidyl-tRNA synthetase (HRS) variant polypeptide consisting of a sequence shown in SEQ ID NO: 6, 9, and 11, or in a fragment of SEQ ID NO: 6, 9, and 11, and wherein the antibody or antigen binding fragment thereof antagonizes a non-canonical activity of the variant polypeptide of HRS splicing. |